Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,057 patients

Journal of Atrial Fibrillation

Volumn 8, Issue 6, 2016, Pages 66-68

  Garg, Jalaj ^a   Chaudhary, Rahul ^b   Krishnamoorthy, Parasuram ^c   Shah, Neeraj ^a   Bozorgnia, Babak ^a   Natale, Andrea ^d  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Einstein Healthcare Network   (United States)

^d TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation ablation; Complications

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN;

ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CATHETER ABLATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GROIN HEMATOMA; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEUROLOGICAL COMPLICATION; PERICARDIAL EFFUSION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84975880614     PISSN: None     EISSN: 19416911     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(4):632-96 e21.
2. Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol. 2015;187:426-9.
3. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, et al. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2015;38(2):155-63.
4. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Heart Rhythm. 2015;12(6):1162-8.
5. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol. 2015;115(1):47-51.
6. Lu D, Liu Q, Wang K, Zhang Q, Shan Q. Meta-analysis of Efficacy and Safety of Apixaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Pacing Clin Electrophysiol. 2015.
7. Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Card Electrophysiol. 2013;37(3):213-21.
8. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol. 2014;113(7):1173-7.
9. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace. 2013;15(10):1407-11.
10. Providencia R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart. 2014;100(4):324-35.
11. Di Biase L, Natale A. Apixaban is dear to me, but dearer still is warfarin. Pacing Clin Electrophysiol. 2015;38(2):153-4.